Omeros (OMER) Amortization of Deferred Charges (2010 - 2025)
Omeros' (OMER) quarterly Amortization of Deferred Charges came in at $8.7 million in Q4 2025, up 260.77% year-on-year from $2.4 million in Q4 2024, and up 473.54% quarter-over-quarter from $1.5 million in Q3 2025.
Omeros (OMER) Amortization of Deferred Charges (2010 - 2025) Analysis & Trends
Omeros has disclosed Amortization of Deferred Charges across 16 years of filings, most recently posting $8.7 million for Q4 2025.
- Amortization of Deferred Charges for Q4 2025 came in at $8.7 million, up 260.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.5 million (up 275.18% YoY), and the FY2025 annual result was $3.9 million, up 184.28% from the prior year.
- Amortization of Deferred Charges came in at $8.7 million for Q4 2025 at Omeros, up from $1.5 million in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $8.7 million in Q4 2025 to a low of -$5.4 million in Q4 2024.
- The 5-year median for Amortization of Deferred Charges is $440000.0 (2021), against an average of $462526.3.
- Peak annual rise in Amortization of Deferred Charges reached 950.0% in 2025, while the deepest fall reached 719.48% in 2025.
- Omeros' Amortization of Deferred Charges stood at $440000.0 in 2021, then sank by 409.32% to -$1.4 million in 2022, then jumped by 236.15% to $1.9 million in 2023, then plunged by 391.1% to -$5.4 million in 2024, then soared by 260.77% to $8.7 million in 2025.
- The last three Amortization of Deferred Charges figures came in at $8.7 million (Q4 2025), $1.5 million (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Omeros | 737.87 Mn | 602.55 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.67 Mn |
| Dec 31, 2025 | 8.67 Mn |
| Sep 30, 2025 | 1.51 Mn |
| Sep 30, 2025 | 1.51 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Mar 31, 2025 | -1.91 Mn |
| Mar 31, 2025 | -1.91 Mn |
| Dec 31, 2024 | -5.39 Mn |
| Dec 31, 2024 | -5.39 Mn |
| Sep 30, 2024 | 144,000.00 |
| Sep 30, 2024 | 144,000.00 |
| Jun 30, 2024 | 599,000.00 |
| Jun 30, 2024 | 599,000.00 |
| Mar 31, 2024 | 308,000.00 |
| Mar 31, 2024 | 308,000.00 |
| Dec 31, 2023 | 1.85 Mn |
| Dec 31, 2023 | 1.85 Mn |
| Jun 30, 2023 | -477,000.00 |
| Jun 30, 2023 | -477,000.00 |